Vactech and Provention Bio announce publication of proof-of-concept data for a preclinical prototype of coxsackievirus B vaccine

Provention Bio and Vactech Announce Publication of Proof-of-Concept Data for a Preclinical Prototype of Coxsackievirus B Vaccine
-- The preclinical prototype vaccine is well-tolerated and provides strong protection against coxsackievirus B infections and diabetes in relevant animal models
-- Results provide a solid scientific basis for human trials with Provention's PRV-101 vaccine

Read article (external site)